Pain management

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Ripamonti, C I ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Assessment; Bone pain; Cancer pain; Neuropathic pain; Prevalence; Treatment

Indexed keywords

ANALGESIC AGENT; BUPRENORPHINE; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; FENTANYL CITRATE; METHADONE; MORPHINE; MORPHINE SULFATE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO;

ABDOMINAL PAIN; ANALGESIA; ARTICLE; BREAKTHROUGH PAIN; CANCER PAIN; CHRONIC DRUG ADMINISTRATION; CONFUSION; CONSTIPATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPIC SURGERY; ENDOSCOPIC ULTRASOUND GUIDED CELIAC PLEXUS NEUROLYSIS; GASTROINTESTINAL HEMORRHAGE; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; MYOCLONUS; NAUSEA; NEUROPATHIC PAIN; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PANCREATIC PAIN; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTOPERATIVE PAIN; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING;

EID: 84866759962     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds360     Document Type: Article

References (65)

1. International Association for the Study of Pain (IASP). Subcommittee on taxonomy. Classification of chronic pain. Descriptors of chronic pain syndromes and definition of pain terms. Pain 1986; 3 (suppl): S1-S225.
2. Koh M, Portenoy RK. Cancer pain syndromes. In Bruera ED, Portenoy RK (eds), Cancer pain. assessment and management. Cambridge, UK: Cambridge University Press 2010; 53-85.
3. Van den Beuken-van Everdingen MHJ, De Rijke JM, Kessels AG et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18: 1437-1449.
4. Sun V, Borneman T, Piper B et al. Barriers to pain assessment and management in cancer survivorship. J Cancer Surviv 2008; 2: 65-71.
5. Burton AW, Fanciullo GJ, Beasley RD et al. Chronic pain in cancer survivor: a new frontier. Pain Med 2007; 8: 189-198.
6. Costantini M, Ripamonti C, Beccaro M et al. Prevalence, distress, management and relief of pain during the last three months of cancer patients' life. Results of an Italian mortality follow-back survey. Ann Oncol 2009; 20: 729-735.
7. Breivik H, Cherny N, Collett F et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009; 20: 1420-1433.
8. Apolone G, Corli O, Caraceni A et al. Pattern and quality of care of cancer pain management. Results from the cancer pain outcome research study group. Br J Cancer 2009; 100: 1566-1574.
9. Bandieri E, Sichetti D, Luppi M et al. Is pain in haematological malignancies under-recognised? The results from Italian ECAD-O survey. Leukemia Res 2010; 34: e334-e335.
10. Morselli M, Bandieri E, Zanin R et al. Pain and emotional distress in leukemia patients at diagnosis. Leukemia Res 2010; 34: e67-e68.
11. Frankish H. 15 million new cancer cases per year by 2020, says WHO. The Lancet 2003; 361: 1278.
12. Caraceni A, Cherny N, Fainsinger R et al. The Steering Committee of the EAPC Research Network. Pain measurement tools and methods in clinical research in palliative care: recommendations of an expert working group of the European Association of Palliative Care. J Pain Symptom Manage 2002; 23: 239-255.
13. World Health Organization. Cancer Pain Relief. Geneva: World Health Organization 1986.
14. World Health Organization. Cancer Pain Relief, 2nd edition. Geneva: World Health Organization 1996.
15. Ripamonti C, Bandieri E, Roila F, on behalf of the ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22(Suppl 6): 69-77.
16. Paice JA, Ferrell B. The management of cancer pain. CA Cancer J Clin 2011; 61: 157-182.
17. Vignaroli E, Bennett MI, Nekolaichuk C et al. Strategic pain management: the identification and development of the International Association for Hospice and Palliative Care (IAHPC) Opioid Essential prescription package. J Palliative Med 2012; 15(2): 186-191.
18. Ripamonti C, Bandieri E. Cancer pain. Crit Rev Oncol Hematol 2009; 70: 145-149.
19. McNicol E, Strassels S, Gouds L et al. NSAIDs or paracetamol, alone or combined with opioids, for cancer pain (Cochrane Review). In the Cochrane Library Issue 1, 2006. Chichester: John Wyley.
20. Bennett NI. Effectiveness of antiepilectic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med 2011; 25: 553-559.
21. Carlson RW, Borrison RA, Sher HB et al. A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac, tromethamine, acetaminophen plus codeine, and placebo in cancer pain. Pharmacotherapy 1990; 10: 211-216.
22. Strobel VE. Drug therapy in severe tumor pain: comparative study of a new combination preparation versus diclofenac-Na. Fortsch Med 1992; 110: 411-414.
23. Eisenberg E, Berkey C, Carr DB et al. Efficacy and safety of nonsteroidal anti-inflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994; 12: 2756-2765.
24. Moore A, Collins S, Carroll D et al. Paracetamol with and without codeine in acute pain: a quantitative systematic review. Pain 1997; 70: 193-201.
25. Freynhagen R, Zenz M, Strumpf M. WHO step II: clinical reality or a didactic instrument? Der Schmerz 1994; 8: 210-215.
26. Mercadante S, Porzio G, Ferrera P et al. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 2006; 31: 242-247.
27. Maltoni M, Scarpi E, Modenesi C et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 2005; 13: 888-894.
28. Tassinari D, Drudi F, Rosati M et al. The second step of the analgesic ladder and oral tramadol in the treatment of mild to moderate cancer pain. A systematic review. Palliat Med 2011; 25(5): 410-423.
29. De Conno F, Ripamonti C, Fagnoni E et al. The MERITOStudy: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during 'titration phase' in patients with cancer pain. Palliat Med 2008; 22: 214-221.
30. Ripamonti C, Campa T, Fagnoni E et al. Normal release oral morphine starting dose in cancer patients with pain. Clin J Pain 2009; 25: 386-390.
31. Hanks GW, De Conno F, Ripamonti C et al. Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care. BMJ 1996; 312: 823-826.
32. Caraceni A, Hanks G, Kaasa S et al. Use of opioid analgesics in the treatment of cancer pain: evidenced-based recommendations from the EAPC. Lancet Oncol 2012; 13: e58-e68.
33. Radbruch L, Loick G, Schulzeck S et al. Intravenous titration with morphine for severe cancer pain: report of 28 cases. Clin J Pain 1999; 15(3): 173-178.
34. Mercadante S, Villari P, Ferrera P et al. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 2002; 95: 203-208.
35. Harris JT, Suresh Kumar K, Rajagopal MR. Intravenous morphine for rapid control of severe cancer pain. Palliat Med 2003; 17: 248-256.
36. King SJ, Reid C, Forbes K et al. A systematic review of oxycodone in the management of cancer pain. Palliat Med 2011; 25(5): 454-470.
37. Pigni A, Brunelli C, Caraceni A. The role of hydromorphone in cancer pain treatment: a systematic review. Palliat Med 2011; 25(5): 471-477.
38. Ripamonti C, Bareggi C. Pharmacology of opioid analgesia: clinical principles. In Bruera E, Portenoy R. (eds). Cancer pain. Assessment and management, Vol. 11. Cambridge, UK: Cambridge University Press 2010; 195-229.
39. Ventafridda V, Ripamonti C, Bianchi M et al. A randomized study on oral administration of morphine andmethadone in the treatment of cancer pain. J Pain Symptom Manage 1986; 1: 203-207.
40. Ripamonti C, Groff L, Brunelli C et al. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998; 16: 3216-3221.
41. Ripamonti C, Bianchi M. The use of methadone for cancer pain. Hematol Oncol Clin North Am 2002; 16: 543-555.
42. De Conno F, Groff L, Brunelli C et al. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996; 14: 2836-2842.
43. US Food and DrugAdministration. FDA issues second safety warning on fentanyl skin patch [news release]. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01762.html.
44. Cachia E, Ahmedzai SH. Transdermal opioids for cancer pain. Curr Opin Support Palliat Care 2011; 5: 15-19.
45. Cherny N, Ripamonti C, Pereira J et al. Expert Working Group of the EAPC Network. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19: 2542-2554.
46. Mercadante S, Casuccio A, Fulfaro F et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001; 19: 2898-2904.
47. Benitez-Rosario MA, Feria M, Salinas-Martin A et al. Opioid switching from transdermal fentanyl to oral methadone in patientswith cancer pain. Cancer 2004; 101: 2866-2873.
48. Mercadante S, Ferrera P, Villari P et al. Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol 2005; 23: 5229-5234.
49. Burza M, Ginobbi P, Fusco G et al. Transdermal route as an alternative to oral administration of opioids in cancer pain. Clin Ter 1998; 14: 277-280.
50. Garcia de Paredes ML, del Moral Gonzalez F, Martinez del Prado P et al. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the on study. Ann Oncol 2011; 22: 924-930.
51. Puli SR, Reddy JB, Bechtold ML et al. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain. A meta-analysis and systematic review. Dig Dis Sci 2009; 54: 2330-2337.
52. Wyse JM, Carone M, Paquin SC et al. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable cancer. J Clin Oncol 2011; 29: 3541-3546.
53. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 3: 273-281.
54. Haugen DF, Hjermstad MJ, Hagen N et al. Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain 2010; 149(3): 476-482.
55. Greco MT, Corli O, Montanari M et al. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients. Results from the cancer pain outcome research and study group. Clin J Pain 2011; 27: 9-18.
56. Zeppetella G, Riberio MDC. Opioids for the management of breakthrough episodic pain in cancer patients. Cochrane Database Syst Rev 2006; 1: CDOO4311.
57. Vissers D, Stam W, Nolte T et al. Efficacy of intranasal fentanyl spray vs other opioids for breakthrough pain in cancer. Curr Med Res Opin 2010; 26: 1037-1045.
58. Portenoy RK, Burton AW, Gabrail N et al. the Fentanyl Pectin Nasal Spray 043 Study Group. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010; 151: 617-624.
59. Coluzzi PH, Schwartzberg L, Conroy JD et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate OTFC and morphine sulphate immediate release MSIR. Pain 2001; 1-2: 123-130.
60. Mercadante S, Radbruch L, Davies AN et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain- an open label, randomized, cross-over trial. Curr Med Res Opin 2009; 25(11): 2805-2815.
61. Davies A, Sitte T, Elsner F et al. Consistency of efficacy, patient accettability and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulphate in breakthrough cancer pain. J Pain Symptom Manage 2011; 41: 358-366.
62. Uberall MA, Muller-Schwefe Gerhard HH. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin 2011; 27(7): 1385-1394.
63. Ripamonti C, Pessi MA, Boldini S. Supportive Care in Cancer Unit (SCCU) at the NCI of Milan: a New Integrated Model of Medicine in Oncology. Curr Opin Oncol 2012; 24: 391-396.
64. Sichetti D, Bandieri E, Romero M et al. for ECAD Working Group (file: ECAD working group .doc). Impact of setting of care on pain management in patients with cancer: a multicentre cross-sectional study. Ann Oncol 2010; 21: 2088-2093.
65. Ripamonti C, Santini D, Maranzano E et al. On Behalf of the ESMO Guideline Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012; 23: 19 (Suppl 7): vii139-vii154.